You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
USE OF DNATrax TO MODEL THE TRANSPORT OF PARTICULATE MATTER IN URBAN ENVIRONMENTS
SBC: DNATREK, LLC Topic: NIEHSDESCRIPTION provided by applicant Science based strategies for quantifying and mitigating the impact of anthropogenic emissions on public health are essential for the sustainability of cities Similar strategies can also be used to develop and assess the effectiveness of a national defense system against terrorist attacks with airborne biological agents and protect against the spread of airborn ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A biochemical companion diagnostic platform to measure kinase inhibitor pharmacodynamics in leukemia
SBC: MICROFLUIDIC INNOVATIONS, LLC Topic: 102DESCRIPTION provided by applicant Kinase inhibitors created a new paradigm in chemotherapy and are a major focus of new oncology drug development The Bcr Abl inhibitor imatinib was a breakthrough drug for chronic myelogenous leukemia with overwhelming early results however at least of patients are either intolerant resistant or experience recurrence within years and individual respo ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of a Novel Membrane Protein Solubilization/Stabilization Screen
SBC: SOLUBLE THERAPEUTICS, INC Topic: 100DESCRIPTION provided by applicant The increasing output of new integral membrane protein IMP structures is partially due to the availability of an increasing number of chemical variables such as detergents detergent like molecules lipids and solubilizing stabilizing additives It is clear that specific combinations and concentrations of these different variables are often necessary to impr ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Retargeting FDA Approved Anticancer Liposomal Drugs to Cancer Stem Cells
SBC: ZoneOne Pharma Topic: ODESCRIPTION provided by applicant The goal of this research is to develop a ligand product and facile method to use it to target FDA approved liposomal anticancer drugs to cancer stem cells that overexpress CD We have devised a highly efficient chemo enzymatic synthesis of a hyaluronan lipid HA lipid ligand and have teamed with ZoneOne Pharma to develop a simple and robust micelle transfer ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors
SBC: SignalRx Pharmaceuticals Inc. Topic: 102DESCRIPTION provided by applicant There is an unmet need to inhibit the key cancer promoting transcription factor MYC MYC both cMYC and MYCN acts downstream of many cell receptor complexes and signal transduction pathways to activate genes that drive cancer cell growth and proliferation To date small molecule inhibitors of MYC have been elusive An innovative approach would be to indirectl ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Targeting C/EBP-beta Phosphorylation for the Treatment of Lung Fibrosis
SBC: XFIBRA, LLC Topic: NHLBIDESCRIPTION provided by applicant Activation of lung myofibroblasts LMF is responsible for the development of lung fibrosis in chronic lung diseases of all causes and remarkably LMF clearance by apoptosis may prevent development of lung fibrosis and lung injury and possibly allow recovery from reversal of lung fibrosis There is full agreement among tissue fibrosis experts that inhibiting o ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Mechanistic Studies of a Novel Small Molecule HIV Inhibitor
SBC: ADVANCED GENETIC SYSTEMS, INC. Topic: 100DESCRIPTION provided by applicant There is a significant need for novel HIV therapies given the emergence of viruses resistant to existing drug regimens The Rev RRE protein RNA interaction in HIV plays an essential role in the transport of viral mRNA from the nucleus to the cytoplasm where it can be translated or packaged Previously we identified the thienopyridine scaffold that inhibited HIV ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of a biomimetic small molecule therapeutic for neovascular retinal diseases
SBC: EyeMedix, Inc. Topic: NDESCRIPTION provided by applicant Retinal diseases including age related macular degeneration AMD diabetic retinopathy DR diabetic macular edema DME and retina vein occlusion RVO are the leading causes of vision loss and blindness in people over years old According to the NEI in nearly million people in the U S suffered from some form of these diseases whose prevalen ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Diagnosing aggressive prostate cancer by spectroscopic photoacoustic tomography
SBC: Vibronix, Inc. Topic: 102DESCRIPTION provided by applicant Prostate cancer PCa is the No killer among male cancer patients The ultimate test is based on transrectal ultrasound guided needle biopsy and histological examination of fixed prostate tissues This conventional diagnostic procedure is invasive missing cases of cancer due to small sampling volume Moreover it leads to an overtreatment of patients du ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant system
SBC: FasCure Therapeutics LLC Topic: NIAIDDESCRIPTION provided by applicant FasCure Therapeutics focuses on the development of adjuvant systems to generate prophylactic and therapeutic immune responses The major objective of this Phase STTR proposal is to reformulate a lead plague subunit vaccine with a novel adjuvant system to improve its protective efficacy Yersinia pestis is the causative agent of bubonic and pneumonic plague ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health